 Cecilia Low Wang
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperglycemia | 8 | 2024 | 335 | 2.640 |
Why?
| | Diabetes Mellitus, Type 2 | 15 | 2024 | 2236 | 2.150 |
Why?
| | Blood Glucose | 13 | 2024 | 2008 | 1.490 |
Why?
| | Diabetes Mellitus | 7 | 2021 | 988 | 1.400 |
Why?
| | Hypoglycemic Agents | 6 | 2024 | 1081 | 1.120 |
Why?
| | Lower Extremity | 3 | 2021 | 356 | 1.110 |
Why?
| | Cardiovascular System | 2 | 2019 | 134 | 1.100 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 1904 | 1.020 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 435 | 0.950 |
Why?
| | Peripheral Arterial Disease | 3 | 2021 | 402 | 0.940 |
Why?
| | Prediabetic State | 2 | 2024 | 241 | 0.920 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 420 | 0.720 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2024 | 551 | 0.710 |
Why?
| | Epidemics | 1 | 2021 | 76 | 0.690 |
Why?
| | Hypoglycemia | 1 | 2024 | 413 | 0.660 |
Why?
| | Insulin Resistance | 7 | 2024 | 1214 | 0.640 |
Why?
| | Drug Approval | 1 | 2019 | 82 | 0.630 |
Why?
| | Early Termination of Clinical Trials | 1 | 2018 | 15 | 0.620 |
Why?
| | Glucocorticoids | 3 | 2022 | 554 | 0.610 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 246 | 0.590 |
Why?
| | Sample Size | 1 | 2018 | 138 | 0.590 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1006 | 0.570 |
Why?
| | Insulin | 10 | 2024 | 2219 | 0.570 |
Why?
| | Atherosclerosis | 3 | 2017 | 360 | 0.550 |
Why?
| | Ischemia | 1 | 2018 | 383 | 0.510 |
Why?
| | Aspirin | 1 | 2018 | 348 | 0.500 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 36 | 0.500 |
Why?
| | Drugs, Investigational | 1 | 2015 | 31 | 0.500 |
Why?
| | Patient Care Planning | 1 | 2016 | 151 | 0.490 |
Why?
| | Hospitals | 2 | 2017 | 654 | 0.480 |
Why?
| | Patient Selection | 1 | 2018 | 725 | 0.460 |
Why?
| | Endovascular Procedures | 1 | 2018 | 297 | 0.450 |
Why?
| | Algorithms | 2 | 2023 | 1618 | 0.440 |
Why?
| | Swine, Miniature | 1 | 2013 | 73 | 0.430 |
Why?
| | Insulin, Long-Acting | 2 | 2024 | 52 | 0.420 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 309 | 0.410 |
Why?
| | Obesity | 6 | 2023 | 2805 | 0.350 |
Why?
| | Glucose | 3 | 2024 | 995 | 0.350 |
Why?
| | Hospitalization | 2 | 2016 | 1960 | 0.340 |
Why?
| | Enteral Nutrition | 3 | 2024 | 175 | 0.340 |
Why?
| | Insulin, Isophane | 2 | 2024 | 17 | 0.340 |
Why?
| | Humans | 34 | 2024 | 125131 | 0.340 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 399 | 0.320 |
Why?
| | Diabetes Complications | 2 | 2013 | 231 | 0.280 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 459 | 0.260 |
Why?
| | Dietary Fats | 3 | 2012 | 332 | 0.220 |
Why?
| | Heart Failure | 1 | 2016 | 2154 | 0.210 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2006 | 246 | 0.210 |
Why?
| | Treatment Outcome | 5 | 2019 | 9790 | 0.210 |
Why?
| | Glucose Intolerance | 1 | 2024 | 140 | 0.210 |
Why?
| | Diet | 3 | 2015 | 1178 | 0.200 |
Why?
| | Endocrinology | 1 | 2023 | 73 | 0.200 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 75 | 0.190 |
Why?
| | Steroids | 1 | 2022 | 158 | 0.190 |
Why?
| | Risk Factors | 5 | 2019 | 9549 | 0.190 |
Why?
| | Dyslipidemias | 1 | 2023 | 169 | 0.190 |
Why?
| | Patient Admission | 1 | 2012 | 198 | 0.180 |
Why?
| | Dexamethasone | 1 | 2022 | 329 | 0.180 |
Why?
| | Anticholesteremic Agents | 2 | 2017 | 141 | 0.180 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 1998 | 50 | 0.170 |
Why?
| | Diet, Reducing | 2 | 1998 | 84 | 0.170 |
Why?
| | Male | 15 | 2021 | 60792 | 0.160 |
Why?
| | Diabetic Angiopathies | 1 | 2011 | 276 | 0.160 |
Why?
| | Female | 16 | 2021 | 64889 | 0.160 |
Why?
| | Dietary Carbohydrates | 4 | 2012 | 161 | 0.160 |
Why?
| | Inpatients | 1 | 2012 | 414 | 0.160 |
Why?
| | Critical Illness | 1 | 2024 | 719 | 0.150 |
Why?
| | United States | 5 | 2023 | 13613 | 0.150 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 270 | 0.150 |
Why?
| | Hypercholesterolemia | 1 | 2017 | 100 | 0.140 |
Why?
| | Middle Aged | 10 | 2018 | 29112 | 0.140 |
Why?
| | Electronic Health Records | 1 | 2023 | 875 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 2026 | 0.140 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2013 | 60 | 0.130 |
Why?
| | Diet, Diabetic | 1 | 1996 | 34 | 0.130 |
Why?
| | Early Growth Response Protein 1 | 1 | 2006 | 32 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2021 | 658 | 0.130 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 84 | 0.130 |
Why?
| | Nausea | 1 | 2015 | 113 | 0.120 |
Why?
| | Biomarkers | 3 | 2023 | 3736 | 0.120 |
Why?
| | Mexican Americans | 1 | 2015 | 102 | 0.120 |
Why?
| | Caloric Restriction | 2 | 2012 | 97 | 0.120 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2004 | 41 | 0.120 |
Why?
| | Physicians | 1 | 2023 | 836 | 0.120 |
Why?
| | Quality of Life | 2 | 2023 | 2580 | 0.120 |
Why?
| | Aged | 5 | 2021 | 20859 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 304 | 0.120 |
Why?
| | Hypertension | 1 | 2023 | 1257 | 0.120 |
Why?
| | Adiponectin | 1 | 2015 | 233 | 0.110 |
Why?
| | Lactic Acid | 1 | 2015 | 286 | 0.110 |
Why?
| | Dehydroepiandrosterone | 1 | 2004 | 51 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2018 | 1725 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2012 | 990 | 0.110 |
Why?
| | Signal Transduction | 4 | 2012 | 4809 | 0.110 |
Why?
| | Muscle, Skeletal | 2 | 2012 | 1568 | 0.110 |
Why?
| | Androgens | 1 | 2004 | 169 | 0.100 |
Why?
| | Weight Loss | 2 | 1998 | 677 | 0.100 |
Why?
| | Sirtuin 1 | 1 | 2012 | 31 | 0.100 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 198 | 0.100 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 96 | 0.100 |
Why?
| | Disease Management | 1 | 2016 | 599 | 0.100 |
Why?
| | Postmenopause | 1 | 2004 | 310 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 546 | 0.100 |
Why?
| | Phosphorylation | 2 | 2013 | 1694 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2024 | 13708 | 0.100 |
Why?
| | Arteries | 1 | 2013 | 257 | 0.090 |
Why?
| | Estrogens | 1 | 2004 | 337 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2013 | 155 | 0.090 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2012 | 181 | 0.090 |
Why?
| | Adiposity | 1 | 2015 | 529 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2021 | 2325 | 0.090 |
Why?
| | Swine | 1 | 2013 | 786 | 0.090 |
Why?
| | Vasodilation | 1 | 2013 | 462 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2006 | 1210 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3274 | 0.080 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 316 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 393 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2492 | 0.070 |
Why?
| | Cognition | 1 | 2004 | 1069 | 0.070 |
Why?
| | Phosphates | 1 | 2007 | 170 | 0.070 |
Why?
| | Cholesterol, LDL | 2 | 2017 | 341 | 0.060 |
Why?
| | Endocrinologists | 1 | 2023 | 12 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3823 | 0.050 |
Why?
| | Nonlinear Dynamics | 1 | 2023 | 91 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2024 | 373 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2024 | 245 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2012 | 139 | 0.050 |
Why?
| | Adult | 7 | 2016 | 33167 | 0.050 |
Why?
| | Insulin Glargine | 1 | 2012 | 75 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2004 | 1366 | 0.050 |
Why?
| | Albuminuria | 1 | 2012 | 199 | 0.050 |
Why?
| | Animals | 5 | 2013 | 34345 | 0.050 |
Why?
| | Phenotype | 2 | 2023 | 3153 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2012 | 354 | 0.050 |
Why?
| | Calcium | 1 | 2007 | 1211 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2007 | 4159 | 0.050 |
Why?
| | Prospective Studies | 2 | 2021 | 6818 | 0.040 |
Why?
| | Adolescent | 2 | 2015 | 19411 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2023 | 663 | 0.040 |
Why?
| | C-Peptide | 2 | 1998 | 142 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 520 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2012 | 471 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 350 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2012 | 387 | 0.040 |
Why?
| | Dietary Fats, Unsaturated | 1 | 1998 | 23 | 0.040 |
Why?
| | Cholesterol | 2 | 1998 | 390 | 0.040 |
Why?
| | Young Adult | 3 | 2015 | 11384 | 0.040 |
Why?
| | Triglycerides | 2 | 1998 | 551 | 0.040 |
Why?
| | Plaque, Atherosclerotic | 1 | 2017 | 47 | 0.040 |
Why?
| | Survival Rate | 1 | 2021 | 1799 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 841 | 0.030 |
Why?
| | Lipoproteins | 1 | 1998 | 175 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2006 | 16 | 0.030 |
Why?
| | Glucagon | 1 | 1996 | 98 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3047 | 0.030 |
Why?
| | Diet Surveys | 1 | 2015 | 87 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 158 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 1996 | 217 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 6780 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 292 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 214 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2578 | 0.030 |
Why?
| | Lipids | 1 | 1998 | 629 | 0.030 |
Why?
| | Hyperinsulinism | 1 | 2004 | 108 | 0.030 |
Why?
| | Rats | 2 | 2007 | 5517 | 0.030 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2003 | 86 | 0.030 |
Why?
| | Androstadienes | 1 | 2003 | 94 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 666 | 0.030 |
Why?
| | Helminthiasis | 1 | 1993 | 15 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 1996 | 1200 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4824 | 0.030 |
Why?
| | Reference Values | 1 | 2004 | 818 | 0.030 |
Why?
| | Interleukin-4 | 1 | 1993 | 211 | 0.030 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 198 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 307 | 0.020 |
Why?
| | Self Report | 1 | 2015 | 750 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2012 | 134 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1144 | 0.020 |
Why?
| | Psychomotor Performance | 1 | 2004 | 304 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 1993 | 366 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1300 | 0.020 |
Why?
| | PPAR gamma | 1 | 2012 | 190 | 0.020 |
Why?
| | Cattle | 1 | 2003 | 1010 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1233 | 0.020 |
Why?
| | Interferon-gamma | 1 | 1993 | 749 | 0.020 |
Why?
| | Cell Movement | 1 | 2003 | 913 | 0.020 |
Why?
| | Transcription Factor Pit-1 | 1 | 2007 | 24 | 0.020 |
Why?
| | Sodium-Phosphate Cotransporter Proteins | 1 | 2007 | 10 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1528 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2012 | 3471 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4471 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4854 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2016 | 6936 | 0.020 |
Why?
| | Risk | 1 | 2007 | 896 | 0.010 |
Why?
| | Kinetics | 1 | 2007 | 1680 | 0.010 |
Why?
| | Apolipoproteins | 1 | 1998 | 40 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 1047 | 0.010 |
Why?
| | Energy Intake | 1 | 1998 | 463 | 0.010 |
Why?
| | Antigens, Helminth | 1 | 1993 | 18 | 0.010 |
Why?
| | Acute Disease | 1 | 1993 | 1016 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1993 | 997 | 0.000 |
Why?
| | Chronic Disease | 1 | 1993 | 1684 | 0.000 |
Why?
|
|
Low Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|